Implementation of Modern GMP Aspects: Revision of the Annex 2 of the EC GMP Guide as an Example

GMP News
15 November 2007

Implementation of Modern GMP Aspects: Revision of theAnnex 2 of the EC GMP Guide as an Example

The GMP environment is currently changing. Not only the US Food & DrugAdministration modifies its GMP regulations, but also the European MedicinesAgency (EMEA) has taken up an ambitious revision programme for this year (seealso GMP-News from 2 November 2007). As an “outcome” the EMEA recentlyissued the drafted revision of the Annex 2 of the EC GMP Guide for (seealso GMP-News from 9 October 2007).

The draft clearly shows the modern GMP aspects incorporated –as, for instance, risk management. ICH Q9 (Quality Risk Management) is currentlydiscussed everywhere. The EC GMP Guide chapter 1 was modified accordingly, andthe Community Procedures are currently revised with regard to risk managementalso. ICH Q9 itself will supposedly be implemented as Annex 20.

The draft of Annex 2 now also reinforces the requirement for risk baseddecisions. This affects for example

  • The access of personnel in the manufacture of biotechproducts,
  • The management of aseptic processes and
  • Tests with regard to cross contamination.

Other changes currently discussed apply to the EC GMP Guidechapters 3 and 5 concerning “dedicated facilities/dedicated equipment”. TheAnnex 2 draft requires e.g., to take “dedicated equipment/facilities“ intoaccount to be able to reproduce products and avoid cross contaminations. Riskmanagement is present here as well. It also addresses a possible conflict withrequirements regarding work safety. In the changes to the chapters 3 and 5themselves risk management will also be a main focus.

A well-known issue – validation/qualification – will still remain. For instance,the draft addresses validation-related requirements like

  • Validation of decontamination,
  • Validation of air vent filters (for their life span
  • Processes validation (specifically mentioned are allergenand recombinant products, monoclonal anti bodies and gene therapeutics
  • Validation of sterilisation, disinfection, virus removaland –inactivation
  • Requalification of the irradiation
  • Validation of hold time
  • Validation of purification
  • Cleaning Validation (specifically mentioned are genetherapeutics)

The Annex 2 draft can be used as indicator for “modern GMP”.The trend clearly goes toward risk based decisions which the authorities demandfrom pharmaceutical companies – however, paying attention tovalidation/qualification at the same time though.

Get answers to still many open questions with regard tocleaning validation in the 2-day education course Cleaning Validation in Vienna,Austria, from 27-28 May 2008.

Conference Tip:
International Bio-Conference BioProduction Forum – Fill and Finish for Biopharmaceuticals in Schaffhausen, Switzerland, from 28-30 November 2007.


Sven Pommeranz
On behalf of the European Compliance Academy (ECA)



Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information